Managing Mental Health Problems Using the Unique Neuropsychiatric and Diagnosis Platform

Home / Managing Mental Health Problems Using the Unique Neuropsychiatric and Diagnosis Platform

Neuropsychiatric and Diagnosis platform is a powerful assessment and diagnostic tool that will improve the current interventions aimed at enhancing mental health care. Using smartphone devices, the Platform that was founded by Mindstrong Health Company will monitor patterns of interaction to objective measures of brain’s activities.

 

What makes the platform unique

 

The primary purpose of Neuropsychiatric and Diagnostic Platform is to provide continuous computerized biological markers of affection and comprehension. These biological markers include concentration, recall and executive function, and processing speed.

 

Using Google and a smartphone to measure the exact level of understanding by transfiguration of someone’s patterns of scrolling is impressive. This practical approach to evaluation sets the basis for coming up with improved interventions to better mental health treatment. Mental illnesses have over the years become health problems in all parts of the world. The use of smartphones provides a promising solution to this global health concern.

 

This platform is supported by Foresite capital together with ARCH Venture Partners, reveals pelotontherapeutics.com. Some other partners that have joined hands in support of the platform include Optum ventures and Berggruen Holdings.

 

How medical professionals will benefit from the platform

 

The platform that was unveiled by Mindstrong Health Company will allow the medical team to comprehend the main challenges encountered in the care of patients with mental health illnesses. This is according to Jim Tananbaum, the boss of Foresite Capital. This creative platform will largely improve the interventions on which care is provided.

 

Who is Mr. Jim Tananbaum?

 

Jim Tananbaum, the brains behind Foresite Capital and with over $1 billion under his management, has experience in developing companies that specialize in health care and investment. During his days at Harvard Medical School, Jim developed GelTex pharmaceuticals with a minimum capital of $80million. He introduced two drugs that generate revenue of about $1billion. GelTex was later sold for $1.6 billion.

 

According to Business Wire, as an investor, Jim was among the partners that established a practice for the investment of health care services at Sierra Ventures. He developed this practice during the early years of his career. He is also among the proprietors that established Prospect Venture. With his leadership skills, the graduate of Harvard Medical School and Harvard Business School was in charge of the strategic direction of both Amira Pharmaceuticals and Jazz Pharmaceuticals among others. Learn more about Foresite Capital on insidermonkey.com.